Emerging drugs in metastatic breast cancer: an update

Bibliography

• Jemal A, Brey F, Center MM, Global cancer statistics. CA Cancer J Clin 2011;16:69-90
   Google Scholar
• Weiss RB, Woolf SH, Demakos E, Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. J Clin Oncol 2003;21:1825-35
   PubMed Web of Science ®Google Scholar
• Andre F, Slimane K, Bachelot T, Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol 2004;22:3302-8
   PubMed Web of Science ®Google Scholar
• Contents of the SEER Cancer Statistics Review, 1975 – 2005. 2005
   Google Scholar
• Greenberg PA, Hortobagyi GN, Smith TL, Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:2197-205
   PubMed Web of Science ®Google Scholar
• Dufresne A, Pivot X, Tournigand C, Maintenance hormonal treatment improves progression free survival after a first line chemotherapy in patients with metastatic breast cancer. Int J Med Sci 2008;5:100-5
   PubMedGoogle Scholar
• Ravdin PM, Green S, Dorr TM, Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 1992;10:1284-91
   PubMed Web of Science ®Google Scholar
• Vollenweider-Zerargui L, Barrelet L, Wong Y, The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients. Cancer 1986;57:1171-80
   PubMed Web of Science ®Google Scholar
• Rakha EA, El-Sayed ME, Green AR, Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 2007;25:4772-8
   PubMed Web of Science ®Google Scholar
• Hayes DF, Van Zyl JA, Hacking A, Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 1995;13:2556-66
   PubMed Web of Science ®Google Scholar
• Howell A, Robertson JF, Abram P, Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004;22:1605-13
   PubMed Web of Science ®Google Scholar
• Di Leo A, Jerusalem G, Petruzelka L, Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010;28:4594-600
   PubMed Web of Science ®Google Scholar
• Pritchard KI, Rolski J, Papai Z, Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). Breast Cancer Res Treat 2010;123:453-61
   PubMed Web of Science ®Google Scholar
• Robertson JF, Osborne CK, Howell A, Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003;98:229-38
   PubMed Web of Science ®Google Scholar
• Dodwell D, Coombes G, Bliss JM, Combining fulvestrant (Faslodex) with continued oestrogen suppression in endocrine-sensitive advanced breast cancer: the SoFEA trial. Clin Oncol (R Coll Radiol) 2008;20:321-4
   PubMed Web of Science ®Google Scholar
• Bergh J, Jonsson P, Lidbrink E, First results from FACT – an open-label, randomized phase III study investigating loading dose of fulvestrant combined with anastrozole versus anastrozole at first relapse in hormone receptor positive breast cancer. Cancer Res 2009;69(24 Suppl):abstract 23
   Google Scholar
• Goss PE, Gwyn KM. Current perspectives on aromatase inhibitors in breast cancer. J Clin Oncol 1994;12:2460-70
   PubMed Web of Science ®Google Scholar
• Klijn JG, Blamey RW, Boccardo F, Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001;19:343-53
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. V.1.2011. Available from: www.nccn.org
   Google Scholar
• Rochlitz C, Ruhstaller T, Lerch S, Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Ann Oncol 2011;22:80-5
   PubMed Web of Science ®Google Scholar
• Alba E, Ruiz-Borrego M, Margeli M, Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. Breast Cancer Res Treat 2010;122:169-76
   PubMed Web of Science ®Google Scholar
• Wolff AC, Wang M, Li H, Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198. Breast Cancer Res Treat 2010;121:111-20
   PubMed Web of Science ®Google Scholar
• Cortes J, Di Cosimo S, Climent MA, Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study. Clin Cancer Res 2009;15:307-14
   PubMed Web of Science ®Google Scholar
• Addeo R, Faiola V, Guarrasi R, Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age. Cancer Chemother Pharmacol 2008;62:285-92
   PubMed Web of Science ®Google Scholar
• Ibrahim NK, Desai N, Legha S, Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002;8:1038-44
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-803
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Krasnojon D, Cheporov S, Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009;27:3611-19
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Coleman R, Gradishar W. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial. Breast Cancer Res Treat 2010;119:717-24
   PubMed Web of Science ®Google Scholar
• Conlin AK, Seidman AD, Bach A, Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 2010;10:281-7
   PubMed Web of Science ®Google Scholar
• Conlin AK, HUdis CA, Bach A, Randomized phase II trial od nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer [abstract 1006]. 2009 ASCO Annual Meeting
   Google Scholar
• Roy V, LaPlant BR, Gross GG, Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol 2009;20:449-53
   PubMed Web of Science ®Google Scholar
• Blum JL, Savin MA, Edelman G, Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 2007;7:850-6
   PubMed Web of Science ®Google Scholar
• Brezden CB, Cantin G, Younus J, An open label phase II study of weekly nab-paclitaxel as first-line therapy for patients with metastatic breast cancer: safety profile [abstract 1127]. 2010 ASCO Annual Meeting
   Google Scholar
• Vahdat LT, Pruitt B, Fabian CJ, Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009;27:2954-61
   PubMed Web of Science ®Google Scholar
• Cortes J, Vahdat L, Blum JL, Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010;28:3922-8
   PubMed Web of Science ®Google Scholar
• Cortes J, O'Shaughnessy J, Loesch D, Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011;377:914-23
   PubMed Web of Science ®Google Scholar
• Twelves C, Cortes J, Vahdat LT, Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer 2010;10:160-3
   PubMed Web of Science ®Google Scholar
• Twelves C, Loesch D, Blum J, Updated survival analysis of a phase III study (EMBRACE) of eribulin mesylate versus treatment of pyhsician's choice in subjects with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane [abstract P16-14-18]. 2010 San Antonio Breast Cancer Symposium
   Google Scholar
• Burris HA III. Preclinical investigations with epothilones in breast cancer models. Semin Oncol 2008;35:S15-21. quiz S39
   PubMed Web of Science ®Google Scholar
• Thomas E, Tabernero J, Fornier M, Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007;25:3399-406
   PubMed Web of Science ®Google Scholar
• Perez EA, Lerzo G, Pivot X, Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25:3407-14
   PubMed Web of Science ®Google Scholar
• Thomas ES, Gomez HL, Li RK, Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210-17
   PubMed Web of Science ®Google Scholar
• Sparano JA, Vrdoljak E, Rixe O, Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2010;28:3256-63
   PubMed Web of Science ®Google Scholar
• Sparano JA, Vrdoljak E, Rixe O, Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2010;28:3256-63
   PubMed Web of Science ®Google Scholar
• Dawood SS, Kristine B, Hortobagyi GN, Giordano SH. Prognosis of women with stage IV breast cancer by HER2 status and trastuzumab treatment: an institutional based review [abstract 1018]. 2008 ASCO Annual Meeting
   Google Scholar
• Cobleigh MA, Vogel CL, Tripathy D, Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48
   PubMed Web of Science ®Google Scholar
• Kaufman B, Mackey JR, Clemens MR, Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009;27:5529-37
   PubMed Web of Science ®Google Scholar
• Marty M, Cognetti F, Maraninchi D, Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-74
   PubMed Web of Science ®Google Scholar
• Gori S, Colozza M, Mosconi AM, Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. Br J Cancer 2004;90:36-40
   PubMed Web of Science ®Google Scholar
• Schaller G, Fuchs I, Gonsch T, Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol 2007;25:3246-50
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Harris LN, Marcom PK, Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003;21:2889-95
   PubMed Web of Science ®Google Scholar
• Pegram MD, Pienkowski T, Northfelt DW, Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004;96:759-69
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
   PubMed Web of Science ®Google Scholar
• Ryan Q, Ibrahim A, Cohen MH, FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 2008;13:1114-19
   PubMed Web of Science ®Google Scholar
• Capri G, Chang J, Chen SC, An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol 2010;21:474-80
   PubMed Web of Science ®Google Scholar
• Toi M, Iwata H, Fujiwara Y, Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. Br J Cancer 2009;101:1676-82
   PubMed Web of Science ®Google Scholar
• Blackwell KL, Burstein HJ, Storniolo AM, Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;28:1124-30
   PubMed Web of Science ®Google Scholar
• Blackwell KL, Pegram MD, Tan-Chiu E, Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol 2009;20:1026-31
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS, Franco SX, Florance A, Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist 2010;15:122-9
   PubMed Web of Science ®Google Scholar
• Sutherland S, Ashley S, Miles D, Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases–the UK experience. Br J Cancer 2010;102:995-1002
   PubMed Web of Science ®Google Scholar
• Metro G, Foglietta J, Russillo M, Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 2011;22:625-30
   PubMed Web of Science ®Google Scholar
• Kaufman B, Trudeau M, Awada A, Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol 2009;10:581-8
   PubMed Web of Science ®Google Scholar
• Cameron D, Casey M, Oliva C, Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 2010;15:924-34
   PubMed Web of Science ®Google Scholar
• Parulaker W, Chapman JW, Aparicio S, Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (NCIC Clinical Trials Group (NCICCCTG) MA.31/GSK EGF 108919. J Clin Oncol 2011;29(Suppl):abstract TPS108
   Google Scholar
• Gomez HL, Doval DC, Chavez MA, Efficacy and safety of lapatinib as first-line treatment for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008;26:2999-3005
   PubMed Web of Science ®Google Scholar
• Finn RS, Press MF, Dering J, Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. J Clin Oncol 2009;27:3908-15
   PubMed Web of Science ®Google Scholar
• Di Leo A, Gomez HL, Aziz Z, Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008;26:5544-52
   PubMed Web of Science ®Google Scholar
• Johnston S, Pippen J Jr, Pivot X, Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-46
   PubMed Web of Science ®Google Scholar
• Lin NU, Dieras V, Paul D, Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009;15:1452-9
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Boku N, Minami H. Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours. Cancer Chemother Pharmacol 2009;65:129-36
   PubMed Web of Science ®Google Scholar
• Dieras V, Limentani S, Romieu G, Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Ann Oncol 2008;19:1255-60
   PubMed Web of Science ®Google Scholar
• Pivot X, Koralewski P, Hidalgo JL, A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008;19:1547-52
   PubMed Web of Science ®Google Scholar
• Besse-Hammer T, Villanueva C, Campone M, A dose-escalating study of XRP6258 in combination with capecitabine, in patients with metastatic breast cancer progressing after anthracycline and taxane therapy: Preliminary results [abstract 1053]. 2009 ASCO Annual Meeting
   Google Scholar
• Schwartzberg LS, Beeram M, Patnaik A, Tesetaxel, an advanced-generation oral taxane, as first-line treatment in women with metastatic breast cancer [abstract 1065]. 2011 ASCO Annual Meeting
   Google Scholar
• Wiseman LR, Markham A. Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 1996;52:606-23
   PubMed Web of Science ®Google Scholar
• Tan WWHillman DW, Salim M, N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial. Ann Oncol 2010;21:493-7
   PubMed Web of Science ®Google Scholar
• Perez EA, Hillman DW, Mailliard JA, Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 2004;22:2849-55
   PubMed Web of Science ®Google Scholar
• Frasci G, D'Aiuto G, Thomas R, Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-Paclitaxel-refractory breast cancer patients. Oncology 2005;68:391-7
   PubMed Web of Science ®Google Scholar
• Awada A, Chan S, Jerusalem G, Significant efficacy in a phase II study of NKTR-102, a novel polymer conjugate of irinotecan, in patients with pre-treated metastatic breast cancer [abstract P6-11-01]. 2010 San Antonio Breast Cancer Symposium
   Google Scholar
• Llombart-Cussac A, Martin M, Harbeck N, A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer. Clin Cancer Res 2007;13:3652-9
   PubMed Web of Science ®Google Scholar
• Llombart-Cussac A, Theodoulou M, Rowland K, Pemetrexed in patients with locally advanced or metastatic breast cancer who had received previous anthracycline and taxane treatment: phase II study. Clin Breast Cancer 2006;7:380-5
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy JA, Clark RS, Blum JL, Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. Clin Breast Cancer 2005;6:143-9
   PubMedGoogle Scholar
• Robert NJ, Conkling PR, O'Rourke MA, Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer. Breast Cancer Res Treat 2011;126:101-8
   PubMed Web of Science ®Google Scholar
• Pippen J, Elias AD, Neubauer M, A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy. Clin Breast Cancer 2010;10:148-53
   PubMed Web of Science ®Google Scholar
• Dent SF, Gertler S, Verma S, A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol 2010;65:557-61
   PubMed Web of Science ®Google Scholar
• Paridaens R, Dirix L, Dumez H, Phase I/II pharmacokinetic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer. Clin Breast Cancer 2007;7:861-6
   PubMed Web of Science ®Google Scholar
• Garin A, Manikhas A, Biakhov M, A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2008;110:309-15
   PubMed Web of Science ®Google Scholar
• Amoroso D, Donati S, Valsuani C, Combination of trastuzumab, oxaliplatin, and docetaxel as first line treatment in HER2-positive metastatic breast cancer patients: First-step results of a phase II trial (HOT trial) [abstract 1132]. 2009 ASCO Annual Meeting
   Google Scholar
• Farhat FS, Ibrahim K, Kattan J, Final results of a phase II study of liposomal cisplatin-vinorelbine combination as first line treatment in Her2/neu negative metastatic breast cancer [abstract e11080]. 2011 ASCO Annual Meeting
   Google Scholar
• Smith JW II, McIntyre KJ, Acevedo PV, Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer. Breast Cancer Res Treat 2009;118:361-7
   Google Scholar
• O'Shaughnessy J, Romieu G, Dieras V, Meta-Analysis of patients with Triple-Negative Breast Cancer (TNBC) from three randomized trials of first-Line Bevacizumab (BV) and chemotherapy treatment for Metastatic Breast Cancer (MBC) [abstract P6-12-03]. 2010 San Antonio Breast Cancer Symposium
   Google Scholar
• Pritchard KI, Thomsen C, Pierga J-Y, Final OS results, including analysis of patients with triple-nagative disease and aged ≥ 70 years, from the Athena study evaluating first line bevacizumab-containing therapy for locally recurrent/metastatic breast cancer [abstract P2-16-06]. 2010 San Antonio Breast Cancer Symposium
   Google Scholar
• Robert NJ, Dieras V, Glaspy J, RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29:1252-60
   PubMed Web of Science ®Google Scholar
• Smith IE, Pierga JY, Biganzoli L, First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. Ann Oncol 2011;22:595-602
   PubMed Web of Science ®Google Scholar
• Miles DW, Chan A, Romieu G, Final OS results from the randomised, double-blind, placebo-controlled, phase III AVADO study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of locally recurrent or metastatic breast cancer [abstract 41]. 2009 San Antonio Breast Cancer Symposium
   Google Scholar
• Traina TA, Tan WW, Dueck AC, N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group trial [abstract 4096]. 2009 San Antonio Breast Cancer Symposium. J Clin Oncol 2010;28:628
   PubMedGoogle Scholar
• Ramaswamy B, Viswanathan S, Carothers S, Phase II study of trastuzumab, docetaxel, and bevacizumab as first-line therapy in HER2-positive metastatic breast cancer [abstract 284]. 2010 ASCO Breast Cancer Symposium
   Google Scholar
• Hurvitz SA, Pegram MD, Lin L-S, Final results of a phase II trial evaluating trastuzumab and bevacizumab as first line treatment of HER2-amplified advanced breast cancer [abstract 6094]. 2009 San Antonio Breast Cancer Symposium
   Google Scholar
• Thomsen C, Pierga J-J, Pritchard KI, First-line bevacizumab combination therapy in triple-negative locally recurrent/metastatic breast cancer. Subpopulation analysis of study MO19391 in > 2000 patients [abstract 6093]. 2009 San Antonio Breast Cancer Symposium
   Google Scholar
• O'Shaughnessy J, Dieras V, Glaspy J, Comparison of sub-group analyses of PFS from three phase III studies of bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer [abstract 207]. 2009 San Antonio Breast Cancer Symposium
   Google Scholar
• Robert N, Dieras V, Glaspy J, Phase III trials of bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer. Summary of selected adverse events [abstract 6083]. 2009 San Antonio Breast Cancer Symposium
   Google Scholar
• Mayer EL, Dhakil S, Patel T, SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol 2010;21:2370-6
   PubMed Web of Science ®Google Scholar
• Brufsky A, Bondarenko IN, Smirnov V, RIBBON-2:A randomized, double blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer [abstract 42]. 2009 San Antonio Breast Cancer Symposium
   Google Scholar
• Burstein HJ, Elias AD, Rugo HS, Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008;26:1810-16
   PubMed Web of Science ®Google Scholar
• Ahlgren P, Thirlwell M, O'Regan R, An open-label study of sunitinib plus exemestane in the first-line treatment of hormone receptor-positive metastatic breast cancer [abstract 11209]. 2009 ASCO Annual Meeting
   Google Scholar
• Blay J-Y, Lluch A, Gutierez M, Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study [abstract 201]. 2009 San Antonio Breast Cancer Symposium
   Google Scholar
• Dirix L, Canon JL, Amadori D, An exporatory study of sunitinib plus docetaxel and trastuzumab for first-line treatment of HER2+ advanced breast cancer [abstract 6088]. 2009 San Antonio Breast Cancer Symposium
   Google Scholar
• Barrios C, Liu M-C, Lee SC, Phase III randomized trial of sunitinib vs capecitabine in patients with previously treated HER2-negative advanced breast cancer [abstract 46]. 2009 San Antonio Breast Cancer Symposium
   Google Scholar
• Wildiers H, Fontaine C, Vuylsteke P, Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2010;123:463-9
   PubMed Web of Science ®Google Scholar
• Curigliano G, Pivot X, Cortes J, A rondomized phase II study of sunitinib vs standard of car efor patients with previously treated advanced triple-negative breast cancer [abstract P6-12-02]. 2010 San Antonio Breast Cancer Symposium
   Google Scholar
• Ferrario C, Charamis H, Oyewole-Eletu S, Phase Ib study of sorafenib and vinorelbine as first-line treatment in patients with metastatic breast cancer [abstract 1093]. 2010 ASCO Annual Meeting
   Google Scholar
• Bianchi G, Loibl S, Zamagni C, Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs 2009;20:616-24
   PubMed Web of Science ®Google Scholar
• Moreno-Aspitia A, Morton RF, Hillman DW, Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol 2009;27:11-15
   PubMed Web of Science ®Google Scholar
• Gomez P, Roche H, Costa F, OS data from SOLTI-0701: A multinational, double blind, placebo-controlled, randomized phase IIb study evaluating the oral combination of sorafenib and capecitabine in patients with locally advanced or metastatic HER2-negative breast cancer [abstract P2-16-01]. 2010 San Antonio Breast Cancer Symposium
   Google Scholar
• Luu T, Frankel P, Chung C, Phase II trial of vinorelbine and sorafenib in metastatic breast cancer [abstract P6-12-07]. 2010 San Antonio Breast Cancer Symposium
   Google Scholar
• Gradishar WJ, Kaklamani V, Prasad Sahoo T, A double-blind, placebo-controlled, phase IIb, study evaluating the efficacy and safety of sorafenib in combination with paclitaxel as a first-line therapy in patients with locally recurrent or metastatic breast cancer [abstract 44]. 2009 San Antonio Breast Cancer Symposium
   Google Scholar
• Baselga J, Roche H, Costa F, SOLTI-0701: A multinational double-blind, randomized phase IIb study evaluating the efficacy and safety of sorafenib compared to placebo when adminestered in combination with capecitabine in patients with locally advanced or metastatic breast cancer [abstract 45]. 2009 San Antonio Breast Cancer Symposium
   Google Scholar
• Bondarde S, Kaklamani V, Prasad Sahoo T, Sorafenib in combination with paclitaxel as a first-line therapy in patients with locally recurrent or metastatic breast cancer: OS results from a double-blind, randomized, placebo-controlled, phase IIb trial [abstract P2-16-03]. 2010 San Antonio Breast Cancer Symposium
   Google Scholar
• Isaacs C, Herbolsheimer P, Liu MC, Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. Breast Cancer Res Treat 2011;125:137-43
   PubMed Web of Science ®Google Scholar
• Tan A, Reiss S, Wong S, Letrozole and sorafenib as first-line therapy in postmenopausal women with hormone receptor-positive metastatic breast cancer: preliminary results [abstract 256]. 2009 ASCO Breast Cancer Symposium
   Google Scholar
• Isaacs C, Wilkinson M, Liu MC, Phase II study of sorafenib with anastrozole to overcome resistance to aromatase inhibitor (AI)s in patients with hormone receptor positive (ER/PR+) AI resistant metastatic braest cancer [abstract 6093]. 2009 San Antonio Breast Cancer Symposium
   Google Scholar
• Rugo HS, Stopeck A, Joy AA, A randomized double blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG 013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC). J Clin Oncol 2007;25:abstract 1003
   Google Scholar
• Miller KD, Trigo JM, Wheeler C, A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 2005;11:3369-76
   PubMed Web of Science ®Google Scholar
• Slamon D, Gomez HL, Kabbinavar FF, Randomized study of pazopanib plus lapatinib versus lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer. J Clin Oncol 2008;26(45s):abstract 16
   PubMedGoogle Scholar
• Krop IE, Beeram M, Modi S, Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010;28:2698-704
   PubMed Web of Science ®Google Scholar
• Isakoff SJ, Baselga J. Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2011;29:351-4
   PubMed Web of Science ®Google Scholar
• Hurvitz S, Dirix L, Kocsis J, Trastuzumab emtansine (T-DM1) versus trastuzumab plus docetaxel in previously untreated HER2-positive metastatic breast cancer [abstract 5001]. ECCO-ESMO 2011
   Google Scholar
• Baselga J, Swain SM. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clin Breast Cancer 2010;10:489-91
   PubMed Web of Science ®Google Scholar
• Gianni L, Llado A, Bianchi G, Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:1131-7
   PubMed Web of Science ®Google Scholar
• Baselga J, Gelmon KA, Verma S, Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010;28:1138-44
   PubMed Web of Science ®Google Scholar
• Portera CC, Walshe JM, Rosing DR, Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res 2008;14:2710-16
   PubMed Web of Science ®Google Scholar
• Baselga J, Cortes J, Fumoleau P, Pertuzumab and trastuzumab : Re-responses to 2 biological agents in patients with HER2-positive breast cancer which had previously progressed during therapy with agent given separately: a new biological and clinical observation [abstract 5114]. 2009 San Antonio Breast Cancer Symposium
   Google Scholar
• Dieras V, Harbeck N, Albain K, A Phase Ib/II trial of trastuzumab with pertuzumab for patients with HER2-positive, locally advanced or metastatic breast cancer: Inetrim efficacy and safety results [abstract P3-14-01]. 2010 San Antonio Breast Cancer Symposium
   Google Scholar
• Dickler MN, Cobleigh MA, Miller KD, Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2009;115:115-21
   PubMed Web of Science ®Google Scholar
• Britten CD, Finn RS, Bosserman LD, A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach. Clin Breast Cancer 2009;9:16-22
   PubMed Web of Science ®Google Scholar
• Twelves C, Trigo JM, Jones R, Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. Eur J Cancer 2008;44:419-26
   PubMed Web of Science ®Google Scholar
• Schuler MH, Uttenreuther-Fischer MM, Piccart-Gebhart MJ, Harbeck N. BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor, for the treatment of patients with HER2-negative metastatic breast cancer after failure of no more than two prior chemotherapies [abstract 1065]. 2010 ASCO Annual Meeting
   Google Scholar
• Hickish T, Wheatlery D, Lin N, Use of BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab [abstract 5060]. 2009 San Antonio Breast Cancer Symposium
   Google Scholar
• Harbeck N, Schmidt M, Harter P, BIBW 2992, a novel irreversibl EGFR/HER1 and HER2 tyrosine kinase inhibitor for the treatment of patients with HER2-negative metastatic breast cancer after failure of no more than two prior chemotherapies [abstract 5062]. 2009 San Antonio Breast Cancer Symposium
   Google Scholar
• Gunzer K, Joly F, Deloizer T, Addition of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2 inhibitor, to treatment continuation of letrozole in estrogen receptor positive metastatic breast cancer progressing on letrozole [abstract 4098]. 2009 San Antonio Breast Cancer Symposium
   Google Scholar
• Starolawska E, Dirix L, Luu T, Safety and efficacy of neratinib plus vinorelbine in the treatment of patients with ErbB2+ metastatic breast cancer pretreated with Anti-HER2 therapy [abstract P3-14-08]. 2010 San Antonio Breast Cancer Symposium
   Google Scholar
• Awada A, Dirix L, Beck J, Safety and efficacy of neratinib (HKI-272) in combination with vinorelbine in ErbB2+ metastatic breast cancer [abstract 5095]. 2009 San Antonio Breast Cancer Symposium
   Google Scholar
• Chow L, Gupta S, Hershman D, Safety and efficacy of neratinib (HKI-272) in combination with paclitaxel in ErbB2+ metastatic breast cancer [abstract 5081]. 2009 San Antonio Breast Cancer Symposium
   Google Scholar
• Tutt A, Robson M, Garber JE, Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376:235-44
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy J, Osborne C, Pippen JE, Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011;364:205-14
   PubMed Web of Science ®Google Scholar
• Moulder S, Mita M, Bradley C, A phase Ib study to assess the safety and tolerability of the PARP inhibitor iniparib (BSI-201) in combination with irinotecan for the treatment of patientss with metastatic breast cancer [abstract P6-15-01]. 2010 San Antonio Breast Cancer Symposium
   Google Scholar
• Zhang J, Zhang XB, Liu JJ, Effects of an mTOR inhibitor RAD001 on human breast cancer stem cells in vitro [abstract PD02-09]. 2010 San Antonio Breast Cancer Symposium
   Google Scholar
• Ellard SL, Clemons M, Gelmon KA, Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009;27:4536-41
   PubMed Web of Science ®Google Scholar
• Chen CS, Chen MM, Imaoka RT, A Phase I pilot study of the oral mTOR inhibitor RAD001in combination with capecitabine for metastatatic breast cancer [abstract 6112]. 2009 San Antonio Breast Cancer Symposium
   Google Scholar
• Jerusalem G, Fasolo A, Dieras V, Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 2011;125:447-55
   PubMed Web of Science ®Google Scholar
• Morrow PK, Wulf GM, Ensor J, Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 2011;29:3126-32
   PubMed Web of Science ®Google Scholar
• Cardoso F, Dieras V, Campone M, Eveolimus (Afinitor®) trastuzumab, and paclitaxel or vinorelbine in the treatment of HER-2 positive metastatic breast cancer patients pre-treated with lapatinib-containing therapy: pooled analysis of 2 phase I studies [abstract 5064]. 2009 San Antonio Breast Cancer Symposium
   Google Scholar
• Andre F, Campone M, O'Regan R, Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 2010;28:5110-15
   PubMed Web of Science ®Google Scholar
• Mayer IA, Burris HA, Bendell JC, A phase Ib trial of RAD001, an mTOR inhibitor, with weekly cisplatin and paclitaxel in patients with HER2-negative metastatic breast cancer [abstract 3093]. 2009 San Antonio Breast cancer Symposium
   Google Scholar
• Jerusalem GH, Fasolo A, Massacesi C, Maintenance with everolimus (RAD001) and trastuzumab after discontinuation of chemotherapy in patients with heavily pretreated HER2-positive metastatic breast cancer: pooled data of extension cohorts of phase Ib/II studies [abstract 1041]. 2010 ASCO Annual Meeting
   Google Scholar
• Baselga J, Campone M, Piccart-Gebhart MJ, Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer who are refractory to letrozole or anastrozole: preliminary results of the BOLERO-2 trial [abstract e11058]. 2011 ASCO Annual Meeting
   Google Scholar
• Bachelot T, Bourgier C, Cropet C, TAMRAD: A GINECO randomized phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients with hormone receptor positive, HER2-negative metastatic breast cancer with prior exposure to aromatase inhibitors [abstract S1-6]. 2010 San Antonio Breast Cancer Symposium
   Google Scholar
• Badin F, Romond E, Chambers M, A phase II trial of fulvestrant and RAD001 (everolimus) in patients with metastatic estrogen receptor positive breast cancer after aromatase inhibitor failure, a study in progress [abstract P4-02-05]. 2010 San Antonio Breast Cancer Symposium
   Google Scholar
• Baselga J, Campone M, Piccart-Gebhart MJ, Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer who are refractory to letrozole or anastrozole: preliminary results of the BOLERO-2 trial [abstract 9LBA]. ECCO-ESMO 2011
   Google Scholar
• Jerusalem G, Ellard SL, Fasolo A, Non-infectious pneumonitis in breast cancer patients treated with everolimus (Afinitor®) containing therapy: analysis of five studies [abstract 1115]. 2009 San Antonio Breast Cancer Symposium
   Google Scholar
• Chan S, Scheulen ME, Johnston S, Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005;23:5314-22
   PubMed Web of Science ®Google Scholar
• Carpenter JT, Roche H, Campone M, Randomized phase 3 arm, phase 2 study of temsirolimus (CCI-7702) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2005;23:abstract 564
   Google Scholar
• Peacock NW, Jones SF, Yardley DA, The safety and tolerability of panobinostat in combination with capecitabine +/- lapatinib. A phase I study in HER+ breast cancer [abstract 1115]. 2010 ASCO Annual Meeting
   Google Scholar
• Campone M, Conte P, Amodori D, Phase I trial of panobinostat (LBH589) in combination with trastuzumab in pretreated HER2-positive metastatic breast cancer: preliminary safety, efficacy and pharmacocinetic results [abstract 6101]. 2009 San Antonio Breast Cancer Symposium
   Google Scholar
• Swaby RF, Wang M, Sparano JA, A phase II study of histone deacetylase inhibitor vorinostat, in combination with trastuzumab in patients with advanced metastatic and/or local chest wall recurrent Her-2 amplified breast cancer resistant to trastuzumab-containing therapy: (E1104) a trial of the Eastern Cooperative Oncology Group [abstract 793]. 2009 San Antonio Breast Cancer Symposium
   Google Scholar
• Munster PN, Lacevic M, Thomas S, Clinical phase II study of vorinostat, a hydoxamic type histone deacetylase inhibitor, in combination with tamoxifen tor everse acquired hotmone resistance in breast cancer patients who preogressed on hormone therapy [abstract 6100]. 2009 San Antonio Breast Cancer Symposium
   Google Scholar
• Wardley AM, McCaffrey J, Crown J, Preliminary phase II data suggest that entinostat (SNDX275), a class 1 selective histone deacetylase inhibitor, may resensitize breast cancer patients progressing on aromatase inhibitor (AI) therapy to their AI therapy [abstract 6111]. 2009 San Antonio Breast cancer Symposium
   Google Scholar
• Chen D, Frezza M, Schmitt S, Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 2011;11:239-53
   PubMed Web of Science ®Google Scholar
• Irvin WJ Jr, Orlowski RZ, Chiu WK, Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer. Clin Breast Cancer 2010;10:465-70
   PubMed Web of Science ®Google Scholar
• Awada A, Albanell J, Canney PA, Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. Br J Cancer 2008;98:1500-7
   PubMed Web of Science ®Google Scholar
• Schmid P, Kuhnhardt D, Kiewe P, A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Ann Oncol 2008;19:871-6
   PubMed Web of Science ®Google Scholar
• Trinh XB, Sas L, Laere V, A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer [abstract e11072]. 2011 ASCO Annual Meeting
   Google Scholar
• Schroder CP, Pedersen JV, Chua S, Use of biomarkers and imaging to evaluate the treatment effect of AUY922, an HSP90 inhibitor, in patients with HER2+ or ER+ metastatic breast cancer [abstract e11024]. 2011 ASCO Annual Meeting
   Google Scholar
• Modi S, Ismail-Khan R, Munster P, Phase I dose-escalation study of the heat shock protein 90 inhibitor BIIB021 with trastuzumab in Her2+ metastatic breast cancer [abstract P3-14-02]. 2010 San Antonio Breast Cancer Symposium
   Google Scholar
• Ismail-Khan RR, Marichion DC, Cubitt CL, Jancaster JM. Synergy of ixabepilone and dasatinib in trpile negative breast cancer cell lines [abstract P6-15-17]. 2010 San Antonio Breast cancer Symposium
   Google Scholar
• Morris PG, Abbruzzi A, D'andrea G, A phase I-II trial of dasatinib in combination with weekly paclitaxel for patients with metastatic breast carcinoma [abstract P612-09]. 2010 San Antonio Breast Cancer Symposium
   Google Scholar
• Lipton A, Steger GG, Figueroa J, Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 2008;14:6690-6
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Lipton A, Body JJ, Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132-9
   PubMed Web of Science ®Google Scholar
• Henry DH, Costa L, Goldwasser F, Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-32
   PubMed Web of Science ®Google Scholar
• Rugo HS, Stopeck A, Joy AA, Randomized, double-blind phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer (MBC). J Clin Oncol 2011;29:2459-65
   PubMed Web of Science ®Google Scholar
• de Boer RH, Kaufman PA, White S, Primary analysis of a phase Ib combination study of motesanib (AMG 706) with paclitaxel or docetaxel for the treatment of locally recurrent, unresectable or metastatic breast cancer. 2009 San Antonio Breast cancer Symposium. Abstract Number: 205
   Google Scholar
• Dalenc F, Doisneau-Sixou SF, Allal BC, Tipifarnib plus tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysis. Clin Cancer Res 2010;16:1264-71
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Valero V, Mangalik A, Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res 2010;16:1904-14
   PubMed Web of Science ®Google Scholar
• Britten CD, Finn RS, Bosserman LD, A phase I/II trail of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach. Clin Breast Cancer 2009;9:16-22
   PubMed Web of Science ®Google Scholar
• Chew HK, Barlow WE, Albain K, A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer. Southwest Oncology Group Study 0338. Clin Breast Cancer 2008;8:511-15
   PubMed Web of Science ®Google Scholar
• Mayer EL, Scheulen M, Beckman J, Combination of Tivozanib, an oral inhibitor of VEGFR, with weekly pacliytaxel for metastatic breast cancer: Preliminary results of an ongoing phase I study. 2010 San Antonio Breast cancer Symposium. Abstract Number: P2-16-10
   Google Scholar
• Baselga J, Stemmer S, Pego A, Cetuximab+ cisplatin in estrogen receptor-negative, progesterone receptor-negative, HER2-negative (Triple-negative) metastatic breast cancer: Results of the ramdomized phase II BALI-1 Trial. 2010 San Antonio Breast cancer Symposium. Abstract Number: PD01-01
   Google Scholar
• Holden SN, Beeram M, Krop IE, A phase I study of weekly dosing of Trastuzumab-DM1 (T-DM1) in Patients with advanced HER2+ breast cancer. 2008 ASCO Annual Meeting. Abstract Number: 1029
   Google Scholar
• Yardley DA, Seiler M, Ray-Coquard I, Ridaforolimus (AP23573; MK-8669) in combination with trastuzumab for patients with HER2-positive trastuzumab-refractory metastatic breast cancer: A multicenter phase 2 clinical trial. 2009 San Antonio Breast cancer Symposium. Abstract Number: 3091
   Google Scholar
• Miller K, Ng C, Ang P, Phase II, Open label study of ispinesib in patients with locally advanced or metastatic breast cancer. 2005 San Antonio Breast Cancer Symposium. Abstract Number: 1089
   Google Scholar
• Barton JH, Shih KC, Raefsky E, Amrubicin as second- or third- line treatment for patients with HER2-negative etastatic breast cancer (MBC: A Sarah Cannon Research Institute phase I trial. 2011 SCO Annual Meeting Abstract No 1116
   Google Scholar
• Ramaswamy B, Mrozek E, Kuebler JP, Phase II trial of pyrazoloacridine NSC-66140) in patients with metasttic breast cancer. Invest New Drugs 2011;29:347-51
   PubMed Web of Science ®Google Scholar
• Chia S, Dent S, Ellard S, Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. Clin Cancer Res 2009;15:708-13
   PubMed Web of Science ®Google Scholar
• Slamon D, Gomez HL, Kabbinavar FF, Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2- positive advanced or metastatic breast cancer. 2008 ASCO Annual Meeting. Abstract Number: 1016
   Google Scholar
• Campone M, Dittrich C, Cufer T, Phase II study of the novel epothilone sagopilone (ZK-EPO) in patients with progressive metastatic breast cancer. 2009 San Antonio Breast cancer Symposium. Abstract Number: 6107
   Google Scholar
• Yardley DA, Mcleod M, Schreiber F, A Phase II trial of vinflunine as monotherapy or in combination with trastuzumab with trastuzumab as first-line treatment of metastatic breast cancer. Cancer Inve
   Google Scholar
• Awada A, Albanell J, Canney PA, Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose escalation study. Br J Cancer 2008;98:1500-7
   Google Scholar
• Eichaum MH, Schuetz F, Khbeis T, Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a phase II study. Anticancer Drugs 2007;18:963-8
   Google Scholar